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Abstract
Background: Carbonic anhydrase IX is a hypoxia-induced enzyme that has many biologically
important functions, including its role in cell adhesion and invasion.
Methods: This study was set out to investigate the role of CA IX in a series of 86 oligodendroglial
brain tumors (71 primary and 15 recurrent; 48 pure oligodendrogliomas and 40 mixed
oligoastrocytomas).
Results: 80% of the tumors showed CA IX expression by immunohistochemistry. Tumors with
moderate or strong CA IX expression had decreased level of cell proliferation compared to weak
or no CA IX expression (median 2.9 vs. 5.8, p = 0.015). CA IX correlated with two antioxidative
enzymes, manganese superoxide dismutase (MnSOD) and regulatory gammaglutamylcysteine
synthetase (GLCL-R): CA IX expression was significantly higher in MnSOD-positive tumors (p =
0.008) and decreased in GLCL-R-positive tumors (p = 0.044). In Cox multivariate analysis CA IX
expression, patient age and histological component (pure oligodendroglioma vs. mixed
oligoastrocytoma) showed independent prognostic values (p = 0.009, p = 0.003 and p = 0.022,
respectively), CA IX positivity predicting poorer outcome.
Conclusion: CA IX was proved to be an independent prognostic indicator in oligodendroglial
brain tumors, and it also correlates reversely with cell proliferation. It may have a role in the biology
of oligodendrogliomas, and most interestingly, as it is mainly expressed in tumor tissue, CA IX
could serve as a target molecule for anticancer treatments.
Background
Oligodendrogliomas account for approximately 5–18%
of all intracranial gliomas and they occur primarily in the
frontal or temporal lobes of the cerebrum [1,2]. It has
been suggested that oligodendrogliomas were previously
underdiagnosed, and there are several novel studies where
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mas [3]. Accurate diagnosis is important in the case of oli-
godendrogliomas because the pathophysiology,
treatment options and prognosis vary from that of dif-
fusely infiltrating astrocytomas[1].
There are at least two different genetic pathways for the
tumorigenesis of oligodendrogliomas. Loss of chromo-
somal regions on 1p and 19q is characteristic of oligoden-
drogliomas, but there is also evidence for another subset
of oligodendrogliomas that have amplification of EGFR
oncogene, loss of heterozygosity on chromosome 10 and
homozygous deletion of the CDKN2A tumor suppressor
gene. This seems to exclude the more common genetic
changes in 1p and 19q [4,5].
Antioxidant enzymes and related proteins (AOEs) are part
of the cellular protection mechanisms against functional
and structural damage caused by reactive oxygen species
[6]. Increased oxidant stress and/or diminished levels of
AOEs lead to multiple injurious consequences in living
cells, including susceptibility to genetic alterations and
carcinogenesis. AOEs such as manganese superoxide dis-
mutase (MnSOD), glutathione associated enzymes
(GLCL-C and GLCL-R) and thioredoxin-thioredoxin
reductase (Trx, TrxR) have been shown to correlate with
tumor grade, metastasis and poor prognosis in invasive
carcinomas such as lung and gastrointestinal malignan-
cies and we have earlier studied them in oligodendroglial
brain tumors [7-10].
Carbonic anhydrase IX (CA IX) is a tumor-associated met-
alloenzyme that belongs to the physiologically important
family of at least 13 different mammalian carbonic anhy-
drases, CAs [11-13]. It is localized in the plasma mem-
brane and like other enzymatically active CA isoenzymes
(CA I-IV, VA, VB, VI, VII, XII-XV), it contains four impor-
tant histidine residues: three residues for the coordination
of a zinc ion in the active site and one for a proton shuttle.
CAs catalyze the reversible interconversion between CO2
and HCO3 -, one of the most fundamental chemical reac-
tions in cells. This reaction is essential for organisms as it
influences respiration, pH regulation and homeostasis,
exchange of electrolytes and several metabolic biosyn-
thetic pathways [12-15]. Aberrant changes in this fine
machinery are implicated in many diseases, including
cancer.
CA IX has a special role among human CA isoenzymes
because it can only be found in few normal tissues, but it
is abundant in several tumors, such as colorectal, bladder,
cervical, lung and breast carcinomas [16-18]. Even though
the expression of CA IX in these carcinomas is evident, the
tissues from which the carcinomas are originally derived
are known to be CA IX-negative or they show only low
enzyme expression. Furthermore, the few normal tissues
or cell types that express CA IX, such as gastrointestinal
and gallbladder epithelial cells, have been reported to lose
the expression of CA IX during carcinogenesis [19-22].
This quite exceptional phenomenon makes CA IX an
interesting tumor-associated protein.
CA IX expression is strongly induced by hypoxia. This
transcriptional activation is accomplished via the HIF-1
transcription factor, which accumulates in tissue under
the hypoxic condition that is often present in growing
tumors. That, in turn, is an outcome of poorly organized
and insufficient vasculature in uncontrollably growing
malignant tissue. The HIF-1 transcription factor is a trigger
for several hypoxia-regulated genes linked to cell survival,
proliferation, apoptosis, angiogenesis and metabolism in
tumor cells. The activation of these genes helps the cell to
adapt to the stress caused by low oxygen level in a partic-
ular tissue. Earlier studies have shown that CA IX expres-
sion is induced as early as two hours after HIF activation
and persists for several days, even if HIF-1 expression has
ceased. This means that CA IX reflects both previous and
present hypoxia in cells [23-25]. In addition to the impor-
tant correlation between hypoxia and CA IX expression, it
has been found that CA IX expression correlates with poor
prognosis in various tumors [26-29]. It has also been sug-
gested that CA IX has a direct role in tumor progression
and the regulation of pH balance during tumorigenesis.
CA IX has effects on cell adhesion, too, and it has been
suggested to play a role in tumor invasion through weak-
ening of cell-cell adhesion as E-cadherin is competing for
β-catenin [30]. However, the effect of CA IX on tumor cell
invasion is still under debate as some recent results have
suggested that there is no evidence of such a correlation
[31]. Even though we do not know the exact mechanisms
of CA IX in cancer development, it is undoubtedly a prom-
ising target for anticancer treatments. It is also known that
CA IX is strongly inhibited by aromatic and heterocyclic
sulfonamides, and several other potent inhibitors for CAs
have already been designed [32,33]. These facts prompted
us to investigate the expression of CA IX in a series of his-
topathologically and genetically verified oligodendroglial
brain tumors.
Methods
Patients
We analyzed oligodendroglial tumor samples from 86
patients who underwent surgery during 1980–2004 at
Tampere University Hospital, Turku University Hospital
and Kuopio University Hospital, Finland. 71 patients had
a primary tumor and 15 a recurrent tumor. Of these
tumors 55 were grade II and 31 were grade III. Forty-eight
tumors were pure oligodendrogliomas and 38 were oli-
godendrogliomas with an additional astrocytic compo-
nent (mixed oligoastrocytomas). All the patientsPage 2 of 9
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gross radical tumor resection. The median age of the
patients at the time of operation was 40.0 years (mean
41.5, SD +14.2). The median follow-up time was 3.5 years
(mean 4.9, SD 4.5). During the follow-up, 43 patients
died.
Tumor samples
The tumor samples were fixed in 4% phosphate-buffered
formaldehyde and embedded in paraffin. Paraffin sec-
tions were stained with hematoxylin and eosin. His-
topathological typing and grading were carried out
according to WHO criteria (1) independently by two
experienced neuropathologists. Histologically representa-
tive and most proliferative oligodendroglial tumor
regions were selected by a neuropathologist (HH) and the
samples from these areas were placed in tissue microarray
blocks using a custom-built instrument (Beecher Instru-
ments, Silver Spring, MD, USA). The diameter of the tissue
cores in the microarray block was 600 μm. The tumors in
the microarray analysis comprised both pure oligoden-
drogliomas and mixed oligoastrocytomas (for details, see
Table 1.).
Immunohistochemical procedures
CA IX
The monoclonal antibody M75, which recognizes the N-
terminal proteoglycan domain of human CA IX, has been
described previously [34].
Automated immunostaining, which was performed using
Power Vision+™ Poly-HRP IHC Kit (ImmunoVision Tech-
nologies, Co.) reagents, included the following steps: (a)
rinsing in wash buffer; (b) treatment in 3% H2O2 in
ddH2O for 5 min and rinsing in wash buffer; (c) blocking
with Universal IHC Blocking/Diluent for 30 min and rins-
ing in wash buffer; (d) incubation with the primary anti-
body (M75 for CA IX) or normal rabbit serum (NRS)
diluted 1:200 (M75) or 1:2000 (NRS) in Universal IHC
Blocking/Diluent for 30 min; (e) rinsing in wash buffer
for 3 × 5 min; (f) incubation in poly-HRP-conjugated anti-
rabbit or anti-mouse IgG for 30 min and rinsing in wash
buffer for 3 × 5 min; (g) incubation in DAB (3,3'-diami-
nobenzidine tetrahydrochloride) solution (one drop of
DAB solution A and one drop of DAB solution B in 1 ml)
ddH2O for 6 min; (h) rinsing with ddH2O; (i) CuSO4
treatment for 5 min to enhance the signal; and (j) rinsing
with ddH2O. All procedures were carried out at room tem-
perature. The sections were mounted in Entellan Neu
(Merck; Darmstadt, Germany) and finally examined and
photographed with a Zeiss Axioskop 40 microscope (Carl
Zeiss; Göttingen, Germany).
Antioxidative enzymes
The antibodies for the AOEs were as follows: a polyclonal
rabbit anti-human antibody to MnSOD (a gift from Pro-
fessor J.D. Crapo, National Jewish Medical Center, Den-
ver, CO, dilution 1:1000); rabbit polyclonal anti-human
antibodies to GLCL-C and GLCL-R (a gift from Dr Kavan-
agh, University of Washington, Seattle, WA, dilution
1:1000 for both); a goat polyclonal human antibody to
Trx (American Diagnostica, Greenwich, CT, dilution
1:200); and a polyclonal rabbit anti-rat antibody to TrxR
(a gift from Dr Arne Holmgren, Karolinska Institutet,
Stockholm, Sweden, dilution 1:1000).
The tissue antigens for MnSOD, GLCL-C, GLCL-R, Trx and
TrxR were revealed using the Histostain-Plus Kit (Zymed
Laboratories Inc, South San Francisco, CA) as described
previously [35].
The immunostaining results were evaluated during one
session on a multiheaded microscope by three observers
(HH, SJ, SP or YS) semiquantitatively by dividing the CA
IX and AOE staining reaction into four categories based
on the reactivity of the staining taking equally into
account both the intensity and extent of the staining: 0 =
no immunostaining present; 1 = weak immunostaining,
<10% of the tumor tissue immunostained; 2 = moderate
immunostaining, 10–50% of the tumor tissue immunos-
tained; 3 = strong immunostaining present, >50% of the
tumor tissue immunostained. For the analysis, the four
categories were divided into two groups: the CA IX(-) and
AOE(-) group contained negatively and weakly stained
tumors. The CA IX(+) and AOE(+) group contained
tumors showing moderate or strong immunostaining
[10].
Table 1: The expression of carbonic anhydrase IX in oligodendrogliomas.
CA IX expression N(%) Negative Weak Moderate Strong Total (N)
All tumors 17 (20%) 53 (62%) 9 (10%) 7 (8%) 86
Primary tumors 14 (20%) 46 (65%) 7 (10%) 4 (5%) 71
Recurrent tumors 3 (20%) 7 (47%) 2 (13%) 3 (20%) 15
Pure oligodendrogliomas 10 (21%) 30 (63%) 4 (8%) 4 (8%) 48
Mixed oligoastrocytomas 7 (18%) 23 (61%) 5 (13%) 3 (8%) 38
Grade II 12 (22%) 31 (56%) 7 (13%) 5 (9%) 55
Grade III 5 (16%) 22 (71%) 2 (6,5%) 2 (6,5%) 31Page 3 of 9
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detail in our previous study [10]. Briefly, all the AOEs
(MnSOD, GLCL-C, GLCL-R, Trx, TrxR) were expressed dif-
fusely in the sections. MnSOD had granular and TrxR peri-
nuclear cytoplasmic immunoreactivity and rest of the
AOEs were stained diffusely in the cytoplasm.
The signal for CA IX is both membrane-associated and
intracellular in oligodendroglial tumors. CA IX expression
mainly showed focal accentuation and was found to be
most intense in perinecrotic areas. When necrotic or
microvascular proliferation was present, perinecrotic or
microvessel staining was commonly seen.
The CA IX and AOE stainings represent adjacent sections
in the same area of the tumor.
Cell proliferation
For the analysis of cell proliferation, a mouse monoclonal
antibody MIB-1 recognizing the Ki-67 antigen was used
(Immunotech, S.A. Marseille, France) (dilution 1:40).
After immunostaining, the tissue sections were counter-
stained with methyl green. Proliferative activity was
reported as a percentage of immunopositive nuclei. Anal-
ysis of MIB-1 positive tumor cells was done with a care-
fully standardized image analysis system (CAS-200™
Software, Becton Dickinson & Co., USA) as described pre-
viously [36,37]. Briefly, the analysis was done on areas
that were expressing quantitatively the highest number of
immunopositive nuclei. Twenty microscopic fields (×400
magnification) were counted along a vertical and hori-
zontal axis perpendicular to each other. Endothelial cells,
necrotic and haemorrhagic areas as well as section borders
were omitted.
Apoptotic rate
Apoptosis activity was determined by TUNEL-labeling.
The deparaffinized tumor microarray tissue sections were
first digested with proteinase K (20 μg/ml) for 15 min.
Apoptotic cells were demonstrated using ApopTag In Situ
Apoptosis Detection Kit (Oncor, Inc., Gaithersburg, MD,
USA) according to the manufacturer's instructions. In the
terminal deoxynucleotidyl transferase nick end labeling
method, the recommended concentration was reduced
eightfold. Direct immunoperoxidase detection of digoxi-
genin labeled dUTP was followed by counterstaining in
methyl green [38]. Staining was analyzed by counting all
the tumor cells in the core tissue with an image analysis
system (CAS-200™). The obtained scores were reported as
a percentage of immunopositive nuclei.
Analysis of 1p19q
FISH analysis was performed on tumor cell nuclei isolated
from paraffin embedded sections. The sections were first
deparaffinized with xylene, followed by an ethanol row
with decreasing concentrations (100%, 95%, 70%, and
50% for 10 minutes, respectively). After transfer into dis-
tilled water, the deparaffinized sections were incubated
with 0.1% protease in 0.1 M Tris, 0.07 M NaCl at 37°C for
30 minutes and occasionally agitated. To check cell den-
sity, 5 μl of cell suspension was put on a slide and exam-
ined under the microscope. After preparing the slides
using 10 μl of cell suspension, the slides were air-dried
overnight at room temperature and fixed with 4% buff-
ered formaldehyde for 10 minutes. The slides were used
immediately or stored in sealed boxes at -70°C. FISH
analysis for 1p and 19q were performed with LSI 1p36/LSI
1q25 and LSI19q13/LSI 19p13 probes (Vysis). Hybridiza-
tion was done according to the protocols of Vysis included
in the probe package insert.
Analysis of 1p and 19q loss was done by FISH for 30 most
recent tumor samples. In 24 samples there were both 1p
and 19q deletions, 1 had only 1p deletion, 1 only 19q
deletion, and 4 had no deletions.
Statistical analysis
The analyses were done by comparing CA IX groups based
on the immunostaining reactivity. When stated, CA IX
negative group was compared to CA IX positive group.
In survival analysis overall survival was defined from the
day of surgery until the death of the patient. The death of
patient was considered as an event in the analysis.
Univariate survival analysis was carried out by comparing
all the four CA IX categories. In multivariate survival anal-
ysis the tumors that had no CA IX immunostaining were
compared to those which had weak, moderate or strong
staining. This was done to reach the best prognostic cut-
off possible.
The tests used for statistical analysis were all part of SPSS
11.0 (SPSS Inc., Chicago, Illinois) for Windows software.
Chi-square tests, t-tests, Mann-Whitney tests and Wil-
coxon tests were used, as well as multivariate analysis of
variance (ANOVA). The log-rank test and Cox multivari-
ate analysis were used for the analysis of prognostic fac-
tors. The significance level was set at p < 0.05.
Ethics
The study design was approved by the Ethics committee of
Tampere University Hospital and the National Authority
for Medicolegal Affairs.
Results
Expression of CA IX
CA IX expression was analyzed in 71 primary and 15
recurrent oligodendroglial tumors. The distribution of
immunopositivity for CA IX is shown in Table 1 andPage 4 of 9
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ries (negative, weak, moderate, strong) are shown in Fig-
ure 1A–D.
The intensity of CA IX immunostaining in different tumor
grades is shown in Table 1. There was no significant differ-
ence in CA IX expression between grade II and grade III
tumors or between primary and recurrent tumors or
between pure oligodendroglial tumors and mixed oli-
goastrocytomas. The age of the patients at the time of the
operation did not differ significantly between the CA IX(-
) and CA IX(+) groups.
CA IX expression was significantly higher in MnSOD(+)
tumors (p = 0.008, chi-square test). On the other hand,
CA IX expression was decreased in GLCL-R(+) tumors (p
= 0.044, chi-square test). The other AOEs did not reach
any statistical association with CA IX. In addition, there
was no correlation between CA IX and 1p19q status in our
material.
Analyses for cell proliferation and apoptosis were per-
formed and the results were correlated to CA IX expression
(CA IX(-) vs. CA IX(+) tumors). Cell proliferation index
(MIB-1) was decreased among CA IX(+) tumors. In Ca IX
(+) tumors median was 2.9, mean 3.3, SD ± 4.8 vs.
median 5.8, mean11.9 and SD ± 13.9 in CA IX(-) tumors
(p = 0.015, Mann-Whitney test). No significant difference
was seen in apoptotic activity in CA IX(-) vs. CA IX(+)
tumors.
Survival
Survival analysis was confined to the primary cases. When
the patients with tumors that had no immunostaining for
CA IX were compared in univariate survival analysis with
those who had positive immunostaining for CA IX, the
negative tumors tended to associate with a better survival
rate than their positive counterparts (Figure 2.). However,
this difference did not reach statistical significance.
In Cox multivariate analysis the expression of CA IX,
patient age and histological component (pure oligoden-
droglioma vs. mixed oligoastrocytoma) showed inde-
pendent prognostic significance (p = 0.009, Exp(B) =
7.370; p = 0.003, Exp(B) = 3.422 and p = 0.022, Exp(B) =
0.351). CA IX positivity, older age and astrocytic compo-
nent predicted poorer outcome. Other clinicopathologi-
cal features, including proliferation status and 1p 19q
CA IX expression in the four categories (negative (A), weak (B), moderate (C) and strong (D)) in oligodendroglial brain tumor samplesFigur  1
CA IX expression in the four categories (negative (A), weak (B), moderate (C) and strong (D)) in oligodendroglial brain tumor 
samples. Magnification 400×.Page 5 of 9
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to the prognosis.
Discussion
We investigated the expression of CA IX in a series of oli-
godendroglial brain tumors. We found that CA IX is
expressed in most of these tumors and that it has an inde-
pendent prognostic value, predicting a poor outcome. In
addition, CA IX(+) tumors had decreased cell prolifera-
tion compared to CA IX(-) tumors.
Chromosomal loss of 1p and 19q is a common genotypic
change in oligodendrogliomas. It is commonly used as a
tool to make more precise decisions concerning the treat-
ment. Recently, it has become clear, however, that defects
in single chromosomes, genes, or even the sequential
acquisition of mutations, are not the entire story in tum-
origenesis, given that many cancer susceptibility genes
show a high degree of tissue specificity in their association
with neoplastic transformation. Also in oligodendroglio-
mas and other malignant brain tumors, the acquisition of
a complete neoplastic phenotype is caused by the activa-
tion of several oncogenes and the inactivation of several
growth-suppressor genes, and therefore, a number of tar-
get molecules are required to be involved in an optimal
treatment strategy. There are several characteristics which
are important for such a protein target: The molecule (a)
is expressed only in tumor cells, and in the majority of
tumor cells; (b) is well accessible on the surface of the cell;
(c) is not encoded from a mutated gene, but is derived
from a stable chromosomal area; (d) can be targeted with
a safe drug or inhibitory antibody; (e) is easy to determine
in normal laboratory samples and (f) the costs of diagnos-
tic and therapeutic uses are reasonable.
CA IX is an extremely attractive molecule in cancer
research because it has several important properties that
make it completely unique. First of all, it is mainly
expressed in cancerous tissue. Second, it is expressed in
various solid tumor types, including some very common
ones (for example breast, lung and cervical carcinomas),
which can be quite resistant to chemotherapy and radio-
therapy. Third, the CA IX antigen is exposed to the surface
of the malignant cell, thus making it accessible for anti-
bodies or cancer drugs. Fourth, the structure of the CA IX
molecule is amenable to targeting by drugs and it also has
good selectivity. Fifth, CA IX expression can be easily ver-
ified from tissues with common laboratory protocols.
Sixth, CA inhibitors are already being used in both clinical
applications and new trials [33,39] and more effective and
safer inhibitors are being developed [40]. Therefore, one
could conclude that CA IX indeed exhibits several features
that are necessary for a good target molecule in anticancer
therapy, and at least for now it is clear that in most cases
good cancer treatment includes the best combination of
different treatments supporting one another. CA IX and its
inhibitors could definitely be considered as part of that
kind of treatment strategy in the near future.
CA IX has proved to be a surrogate marker for hypoxia and
it has also been found to correlate with prognosis in sev-
eral cancers (including our present tumor material)
[17,26,27,29,41]. CA IX expression could thus be useful
in the prognostic assessment of certain tumors. For exam-
ple, the previous study by Haapasalo et al showed that it
has a strong association with tumor grade and poor prog-
nosis in astrocytic brain tumors [28]. CA IX immunopos-
itivity was observed in 78% of astrocytic brain tumors
(compared to 80% of oligodendrogliomas in our study).
In addition, both in astrocytic brain tumors and in oli-
godendrogliomas perinecrotic accentuation is quite com-
monly seen. A study by Preusser et al shows that CA IX has
a positive correlation with the presence of necrosis [42].
When necrosis or microvascular proliferation was present,
perinecrotic or microvessel staining was commonly seen
in our present study, too. This could reflect the severe
changes disturbing the tissue (hypoxia, insufficient micro-
vasculature etc.) leading finally to necrosis but also
enhancing the expression of CA IX. Although the expres-
sion of CA IX is common in both astrocytomas and oli-
godendrogliomas, it was more clearly associated to tumor
malignancy grade in astrocytic brain tumors. However,
the unique features of CA IX molecule could be useful
Survival by CA IX in primary oligodendroglial brain tumorsFigure 2
Survival by CA IX in primary oligodendroglial brain tumors.Page 6 of 9
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tions for both of these tumor groups.
A recent study by Birner et al in 60 oligodendroglial
tumors with 1p aberrations showed that CA IX expression
is often accompanied with the expression of hypoxia-
inducible factor 1α (HIF-1α) [43]. They concluded that
when expressed together, they represent a true tissue
hypoxia and not just oncogenic activation, which might
otherwise be the case, at least for HIF-1α. It is already
known that HIF-1α is one of the key factors regulating cel-
lular O2 homeostasis and its activation represent a key
step in angiogenesis and adaptation to hypoxia and thus
the vitality of the tumor. Overexpression of HIF-1α is
shown to be an independent prognostic factor in oli-
godendroglial tumors and interestingly, it also correlates
with the microvessel density in these tumors [44]. They
suggested that as tissue hypoxia is known to diminish the
efficacy of radiotherapy and thus influence the adjuvant
therapy given to the patients, the evaluation of tissue
hypoxia using this combination of hypoxia-markers
would be helpful for recruitment of patients for individu-
alized therapy strategies, e.g. identification of hypoxic
tumors for hyperbaric oxygenation preceding radiother-
apy.
In the present study we found that CA IX was expressed
more often in MnSOD-positive tumors. In our previous
study on AOEs in partly the same subgroup of oligoden-
droglial brain tumors, MnSOD was associated with the
histopathological component (pure oligodendrogliomas
vs. mixed astrocytomas), but failed to show a significant
correlation with patient survival [10]. The association
reported here with CA IX is interesting because CA IX is
known to be induced by hypoxia, and MnSOD in turn is
induced among other factors by hyperoxia. It seems that
CA IX expression and hypoxia are quite consistently asso-
ciated, while factors that induce MnSOD are quite com-
plex and numerous [7,45]. Another possible explanation
for this peculiar association might be that MnSOD and CA
IX expression are associated with different phases of tum-
origenesis in oligodendrogliomas. MnSOD has been sug-
gested to be a tumor suppressor gene [46,47]. The
increased expression of MnSOD may reflect the imbal-
ance during tumorigenesis where cells attempt to control
the tumor environment. As the process advances, the envi-
ronment becomes increasingly hostile for normal cells.
Rapidly growing, poorly organized and improperly prolif-
erated cancer cells lead to insufficient microvasculature
and low pH, suppressing the growth of normal cells even
further, while selectively stimulating the growth of malig-
nant ones. This leads to the activation of hypoxia response
elements and consequently induces a number of genes,
including the CA9 gene, involved in the adaptation to the
stress caused by low oxygen. The association between
MnSOD and CA IX may thus represent partly overlapping
periods of tumorigenesis during which both proteins are
present in neoplastic tissue. Furthermore, the basic reac-
tion of MnSOD where reactive oxygen species superoxide
O2- is converted to H2O2 by MnSOD is known to affect to
HIF-1α, by letting it accumulate into the cytosol. Thus,
MnSOD, HIF-1α and CA IX expressions are representing
an exciting and complicated continuum.
We also found an association between CA IX and prolifer-
ation index (MIB-1). In our material, CA IX(+) tumors
had significantly lower proliferation index than their CA
IX(-) counterparts. This could reflect the severe hypoxia
that is present in the tumor tissue, thus affecting to cells
capability to proliferate. A study by Proescholdt et al
shows that the relationship between CA IX and prolifera-
tion index is quite complicated [48]. They examined the
expression of CA IX and CA XII in different kind of brain
tumors and also in the normal brain. They found an asso-
ciation between CA IX positivity and increasing prolifera-
tion index. However, their material was quite
heterogeneous, and oligodendrogliomas were not
included at all. Despite of that, it can be said that the cor-
relation between CA IX and proliferation is interesting
and should be studied more thoroughly.
Conclusion
In conclusion, CA IX is expressed in the majority of oli-
godendroglial tumors and its expression correlates inde-
pendently with patient survival. It is known to be induced
by hypoxia in the tissue, partly by the same elements that
induce angiogenesis, and it affects the survival of cancer
cells. CA IX seems to play a major role in the pathophysi-
ology of several malignancies, including our material of
oligodendroglial tumors, and it may contribute to the
abnormal cellular environment of malignant brain
tumors by shifting the pH gradient towards higher acidity.
Because of its many unique properties, CA IX can be con-
sidered a good candidate for a target molecule when
designing new anticancer therapies.
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